Join The Conversation Card Front 01 Copy

The Medtechy Daily: November 6

Posted on November 06, 2018 by Medtech[y] Staff

The Medtechy Daily provides the latest news and insight for the medical technology industry, including medical device, biotech and digital health.


Otonomy Announces Third Quarter Earnings and the Selection of OTO-413 Presentation at SFN. Otonomy ($OTIC), a company working to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus, released their earnings and financial highlights for the third quarter of 2018. (Medtechy)

Nevro Revenue Growth Slows in the Third Quarter. Nevro ($NVRO) shares were down 14% in early morning trading as the company reported third quarter earnings, bringing in revenue of $95.6 million versus $82.3 million during the third quarter of 2017, resulting in 16% year-over- year growth. Of Nevro's total revenue, in the quarter, $79.6 million came from the U.S. (Medtechy)

AR ‘flight simulator for surgeons’ offers easy access to valuable training with precise haptic feedback on Mac. Apple’s CEO Tim Cook is known as a big proponent of AR. He said last year that he views it “as a big idea like the smartphone.” While augmented reality is being used for anything from gaming to shopping, navigation to useful tools, one company is making a big difference in how medical professionals train with software considered to be the “flight simulator for surgeons.” (9to5mac)

Healthcare CEOs made $4.6M on average in 2017. On average, healthcare industry CEOs received $4,631,579 in total direct compensation in 2017, according to a study from professional services firm BDO. (Becker's Hospital Review)

Surgical Robotics Market Due for a Shake Up? Intuitive Surgical has been dominant in surgical robotics for years now, but Medtronic and Verb both have systems that are on the horizon and will be in direct competition with the da Vinci, said Roger Smith, who follows the space closely. (MDDI)

Boston Scientific’s Eluvia drug-eluting stent succeeds in long lesions. Boston Scientific (NYSE:BSX) touted one-year data today from an analysis of its Eluvia drug-eluting vascular stent system, showing that the device is safe and effective in patients with long, complex, calcified lesions. (DrugDeliveryBusiness)